429 related articles for article (PubMed ID: 34413126)
1. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T
Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126
[TBL] [Abstract][Full Text] [Related]
2. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
[TBL] [Abstract][Full Text] [Related]
3. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im SA; Nowecki Z; Sohn J; Laurentiis M; Jañez NM; Adamo B; Lee KS; Jung KH; Rubovszky G; Tseng LM; Lu YS; Yuan Y; Maxwell MJ; Haddad V; Khan SS; Rugo HS; Pistilli B
Future Oncol; 2024 Mar; 20(8):423-436. PubMed ID: 37387213
[TBL] [Abstract][Full Text] [Related]
4. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.
Levy BP; Felip E; Reck M; Yang JC; Cappuzzo F; Yoneshima Y; Zhou C; Rawat S; Xie J; Basak P; Xu L; Sands J
Future Oncol; 2023 Jul; 19(21):1461-1472. PubMed ID: 37249038
[TBL] [Abstract][Full Text] [Related]
5. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
[TBL] [Abstract][Full Text] [Related]
6. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
[TBL] [Abstract][Full Text] [Related]
7. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
8. Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models.
Suzuki H; Nagase S; Saito C; Takatsuka A; Nagata M; Honda K; Kaneda Y; Nishiya Y; Honda T; Ishizaka T; Nakamura K; Nakada T; Abe Y; Agatsuma T
Mol Cancer Ther; 2024 Mar; 23(3):257-271. PubMed ID: 38205802
[TBL] [Abstract][Full Text] [Related]
9. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
[TBL] [Abstract][Full Text] [Related]
10. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Shimizu T; Sands J; Yoh K; Spira A; Garon EB; Kitazono S; Johnson ML; Meric-Bernstam F; Tolcher AW; Yamamoto N; Greenberg J; Kawasaki Y; Zebger-Gong H; Kobayashi F; Phillips P; Lisberg AE; Heist RS
J Clin Oncol; 2023 Oct; 41(29):4678-4687. PubMed ID: 37327461
[TBL] [Abstract][Full Text] [Related]
11. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract][Full Text] [Related]
12. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
Bardia A; Krop IE; Kogawa T; Juric D; Tolcher AW; Hamilton EP; Mukohara T; Lisberg A; Shimizu T; Spira AI; Tsurutani J; Damodaran S; Papadopoulos KP; Greenberg J; Kobayashi F; Zebger-Gong H; Wong R; Kawasaki Y; Nakamura T; Meric-Bernstam F
J Clin Oncol; 2024 Apr; ():JCO2301909. PubMed ID: 38652877
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
14. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis.
Gadaleta-Caldarola G; Lanotte L; Infusino S; Gadaleta-Caldarola A; Schipilliti FM; Citrigno C; Petrarota C; Cusmai A; Rizzo A
Cancer Treat Res Commun; 2023; 37():100775. PubMed ID: 37956525
[TBL] [Abstract][Full Text] [Related]
16. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer.
Schipilliti FM; Drittone D; Mazzuca F; La Forgia D; Guven DC; Rizzo A
Heliyon; 2024 Apr; 10(7):e28385. PubMed ID: 38560142
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys.
Nagai Y; Oitate M; Shiozawa H; Ando O
Xenobiotica; 2019 Sep; 49(9):1086-1096. PubMed ID: 30351177
[TBL] [Abstract][Full Text] [Related]
18. Selection of Payloads for Antibody-Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study.
Yao B; Gao X; Dan M; Yuan C; Hu X; Sun Z; Hui X; Liu B; Ouyang P; Chen G
AAPS J; 2022 May; 24(4):70. PubMed ID: 35624189
[TBL] [Abstract][Full Text] [Related]
19. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.
Cheng Y; Yuan X; Tian Q; Huang X; Chen Y; Pu Y; Long H; Xu M; Ji Y; Xie J; Tan Y; Zhao X; Song H
Front Oncol; 2022; 12():951589. PubMed ID: 36620535
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Hingorani P; Zhang W; Zhang Z; Xu Z; Wang WL; Roth ME; Wang Y; Gill JB; Harrison DJ; Teicher BA; Erickson SW; Gatto G; Kolb EA; Smith MA; Kurmasheva RT; Houghton PJ; Gorlick R
Mol Cancer Ther; 2022 Aug; 21(8):1318-1325. PubMed ID: 35657346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]